• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Halogenated fatty acids

Introduction to (S)-4,4,4-Trifluoro-3-hydroxybutyric acid (CAS No. 128899-79-6)

(S)-4,4,4-Trifluoro-3-hydroxybutyric acid (CAS No. 128899-79-6) is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This compound belongs to the class of trifluorinated carboxylic acids and is characterized by the presence of a trifluoromethyl group and a hydroxyl group on the butyric acid backbone. The chiral center at the third carbon position imparts enantiomeric specificity, which is crucial for its biological activities.

The synthesis of (S)-4,4,4-Trifluoro-3-hydroxybutyric acid has been extensively studied, with various methods reported in the literature. One common approach involves the asymmetric synthesis of the chiral center using catalytic asymmetric hydrogenation or enzymatic resolution techniques. These methods ensure high enantiomeric purity, which is essential for pharmaceutical applications where enantiomeric purity can significantly impact the efficacy and safety of a drug.

Recent research has highlighted the potential of (S)-4,4,4-Trifluoro-3-hydroxybutyric acid in various therapeutic areas. One notable application is in the treatment of metabolic disorders, particularly those involving dysregulated lipid metabolism. Studies have shown that this compound can modulate key enzymes involved in fatty acid metabolism, such as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), thereby potentially reducing lipid accumulation in tissues.

In addition to its metabolic effects, (S)-4,4,4-Trifluoro-3-hydroxybutyric acid has been investigated for its anti-inflammatory properties. In vitro and in vivo studies have demonstrated that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, suggesting its potential as an anti-inflammatory agent. This property makes it a promising candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The pharmacokinetic properties of (S)-4,4,4-Trifluoro-3-hydroxybutyric acid have also been studied to understand its behavior in biological systems. Research has shown that this compound exhibits good oral bioavailability and a favorable pharmacokinetic profile, making it suitable for oral administration. Furthermore, its stability in physiological conditions ensures that it remains active during transit through the gastrointestinal tract.

Clinical trials are currently underway to evaluate the safety and efficacy of (S)-4,4,4-Trifluoro-3-hydroxybutyric acid in human subjects. Preliminary results from phase I trials have indicated that the compound is well-tolerated at therapeutic doses with no significant adverse effects reported. These findings are encouraging and pave the way for further clinical development.

The potential applications of (S)-4,4,4-Trifluoro-3-hydroxybutyric acid extend beyond traditional pharmaceuticals. It has also been explored as a building block for the synthesis of more complex molecules with diverse biological activities. For example, it can be used as a precursor for the synthesis of prodrugs designed to enhance drug delivery and reduce side effects.

In conclusion, (S)-4,4,4-Trifluoro-3-hydroxybutyric acid (CAS No. 128899-79-6) is a versatile chiral compound with significant potential in various therapeutic areas. Its unique structural features and biological activities make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its mechanisms of action and therapeutic applications, it is likely that this compound will play an increasingly important role in the future of medicinal chemistry and pharmaceutical science.

• 108211-36-5((R)-4,4,4-Trifluoro-3-hydroxybutanoic acid)
• 99437-70-4(Butanoic acid,4,4,4-trifluoro-3-hydroxy-, ethyl ester, (3S)-)
• 338-03-4(4,4,4-trifluoro-3-hydroxy-3-methyl-butanoic acid)
• 156594-11-5(Butanoic acid, 4,4,4-trifluoro-3-hydroxy-3-methyl-, (S)- (9CI))
• 85571-85-3(Butanoic acid,4,4,4-trifluoro-3-hydroxy-, ethyl ester, (3R)-)
• 1547-36-0(3,3-Bis(trifluoromethyl)3-hydroxypropionic Acid)
• 1260903-04-5(2-Ethyl-4,4,4-trifluoro-3-hydroxybutanoic acid)
• 36610-31-8(3-Hydroxy-3-(trifluoromethyl)pentanedioic acid)
• 400-35-1( )
• 86884-21-1(4,4,4-Trifluoro-3-hydroxybutanoic acid)